ArticleMicrosystems & nanoengineering2026
Parallelized droplet microfluidic mechanoporation enables robust and clogging-resistant intracellular gene delivery.
Article in Microsystems & nanoengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microfluidic Platforms for Exosome Engineering: Scalable Therapeutics for Cancer Immunotherapy and Infectious Diseases.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Microfluidic platforms have emerged as powerful tools for efficient intracellular delivery of exogenous cargo. While droplet microfluidics coupled with cell mechanoporation shows significant potential, its broader adoption is often hindered by channel clogging and limited scalability. To address these challenges, we developed a parallelized droplet-based cell mechanoporation platform with integrated bypass channels. This architecture stabilizes internal pressure and mitigates clogging-induced failure, ensuring robust and continuous operation. The platform achieves delivery efficiencies exceeding 98% and cell viabilities above 80% at a throughput of 2 × 10
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.